Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome
Standard
Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. / Leccese, P; Ozguler, Y; Christensen, R; Esatoglu, SN; Bang, D; Bodaghi, B; Celik, AF; Fortune, F; Gaudric, J; Gül, A; Kötter, I; Mahr, A; Moots, RJ; Richter, J; Saadoun, David; Salvarani, Carlo; Scuderi, Francesco; Sfikakis, Petros P; Siva, Aksel; Stanford, Miles; Tugal-Tutkun, Ilknur; West, Richard; Yurdakul, Sebahattin; Olivieri, Ignazio; Yazici, Hasan; Hatemi, Gulen.
In: SEMIN ARTHRITIS RHEU, Vol. 48, No. 4, 05.2018, p. 752-762.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome
AU - Leccese, P
AU - Ozguler, Y
AU - Christensen, R
AU - Esatoglu, SN
AU - Bang, D
AU - Bodaghi, B
AU - Celik, AF
AU - Fortune, F
AU - Gaudric, J
AU - Gül, A
AU - Kötter, I
AU - Mahr, A
AU - Moots, RJ
AU - Richter, J
AU - Saadoun, David
AU - Salvarani, Carlo
AU - Scuderi, Francesco
AU - Sfikakis, Petros P
AU - Siva, Aksel
AU - Stanford, Miles
AU - Tugal-Tutkun, Ilknur
AU - West, Richard
AU - Yurdakul, Sebahattin
AU - Olivieri, Ignazio
AU - Yazici, Hasan
AU - Hatemi, Gulen
PY - 2018/5
Y1 - 2018/5
N2 - ObjectivesThe aim of this systematic review was to inform the update of European League Against Rheumatism (EULAR) Recommendations for the management of Behçet’s syndrome (BS), on the evidence for the treatment of skin, mucosa and joint involvement of BS.MethodsA systematic literature search, data extraction, statistical analyses and assessment of the quality of evidence were performed according to a pre-specified protocol using the PRISMA guidelines. Studies that assessed the efficacy of an intervention in comparison to an active comparator or placebo for oral ulcers, genital ulcers, papulopustular lesions, nodular lesions or arthritis were included. Where possible, risk ratios were calculated for binary outcomes and mean difference for continuous outcomes.ResultsAmong the 3927 references that were screened, 37 were included in the analyses. Twenty-seven of these assessed mucocutaneous and 17 assessed joint involvement. Twenty-one of these studies were randomised controlled trials (RCTs). RCTs with colchicine, azathioprine, interferon-alpha, thalidomide, etanercept and apremilast showed beneficial results with some differences according to lesion type and gender. These agents were generally well tolerated with few adverse events causing withdrawal from the study.ConclusionsRCTs comprised more than a half (21/37, 57%) of the sources included in the evidence synthesis related to skin, mucosa and joint involvement applicable for the EULAR Recommendations for the management of BS. Differences in the outcome measures that were used across the included studies often made it difficult to combine and compare the results.
AB - ObjectivesThe aim of this systematic review was to inform the update of European League Against Rheumatism (EULAR) Recommendations for the management of Behçet’s syndrome (BS), on the evidence for the treatment of skin, mucosa and joint involvement of BS.MethodsA systematic literature search, data extraction, statistical analyses and assessment of the quality of evidence were performed according to a pre-specified protocol using the PRISMA guidelines. Studies that assessed the efficacy of an intervention in comparison to an active comparator or placebo for oral ulcers, genital ulcers, papulopustular lesions, nodular lesions or arthritis were included. Where possible, risk ratios were calculated for binary outcomes and mean difference for continuous outcomes.ResultsAmong the 3927 references that were screened, 37 were included in the analyses. Twenty-seven of these assessed mucocutaneous and 17 assessed joint involvement. Twenty-one of these studies were randomised controlled trials (RCTs). RCTs with colchicine, azathioprine, interferon-alpha, thalidomide, etanercept and apremilast showed beneficial results with some differences according to lesion type and gender. These agents were generally well tolerated with few adverse events causing withdrawal from the study.ConclusionsRCTs comprised more than a half (21/37, 57%) of the sources included in the evidence synthesis related to skin, mucosa and joint involvement applicable for the EULAR Recommendations for the management of BS. Differences in the outcome measures that were used across the included studies often made it difficult to combine and compare the results.
U2 - 10.1016/j.semarthrit.2018.05.008
DO - 10.1016/j.semarthrit.2018.05.008
M3 - SCORING: Review article
C2 - 29954598
VL - 48
SP - 752
EP - 762
JO - SEMIN ARTHRITIS RHEU
JF - SEMIN ARTHRITIS RHEU
SN - 0049-0172
IS - 4
ER -
